Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Clinical Trial Enrollment

- PMLiVE

AstraZeneca/Amgen’s Tezspire shows promise in phase 3 CRSwNP trial

The severe asthma drug met both of the late-stage study’s co-primary endpoints

- PMLiVE

WHO announces priority endemic pathogens for urgent vaccine development

The study identifies the 17 pathogens that regularly cause diseases in communities

- PMLiVE

UK study shows RSV vaccine could reduce antibiotic use and antimicrobial resistance

The new analysis found that RSV infections lead to 640,000 antibiotic prescriptions every year

- PMLiVE

NICE recommends Blueprint Medicines’ Ayvakyt to treat rare blood disorder

Systemic mastocytosis affects approximately one in every 10,000 people in the UK

- PMLiVE

Medscape Publication is Awarded Poster of Distinction at AASLD

Medscape Education is committed to disseminating the outcomes of the education programs through peer-reviewed publications and posters at leading medical conferences around the world. To this end, Medscape publishes more...

Medscape Education

- PMLiVE

Advancing Education at AASLD 2024

Get ready for an exciting experience at AASLD 2024! The Medscape team is thrilled to be in San Diego from November 15-19 for this year’s AASLD conference, where we will...

Medscape Education

- PMLiVE

Infographic: Advantages & Disadvantages of Different Meeting Formats

Discover the unique pros and cons of in-person, hybrid, synchronous virtual, and asynchronous virtual meetings with our detailed infographic. Perfect for anyone planning efficient and engaging meetings, especially in pharmaceutical...

Impetus Digital

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EC for younger eosinophilic oesophagitis patients

Dupixent is now the first drug in the EU indicated for use in this patient population

- PMLiVE

Novo Nordisk and Ascendis enter $285m partnership for once-monthly GLP-1 drug

The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases

- PMLiVE

Chiesi and Oak Hill enrol first European patient in phase 2b premature birth study

The trial is evaluating OHB-607 for preventing bronchopulmonary dysplasia and other complications

- PMLiVE

Johnson & Johnson’s Balversa granted MHRA approval in bladder cancer

Approximately 10,500 people are diagnosed with bladder cancer every year in the UK

- PMLiVE

FDA approves Journey Medical’s Emrosi to treat inflammatory lesions of rosacea

The long-term skin condition affects more than 16 million people in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links